Evidence map›Paper›PMID 36060028›Full record

ArticleCancer diagnosis & prognosis

Number of Examined Lymph Nodes as a Risk Factor for Recurrence in pT1N+ or pT2-3N0 Gastric Cancer.

Masato Nishimuta, Junichi Arai, Keiko Hamasaki, Yasumasa Hashimoto, Takashi Nonaka, Tetsuro Tominaga, Shosaburo Oyama, Toru Yasutake, Terumitsu Sawai, Takeshi Nagayasu

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masato NishimutaDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Junichi AraiDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Keiko HamasakiDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Yasumasa HashimotoDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Takashi NonakaDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Tetsuro TominagaDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Shosaburo OyamaDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Toru YasutakeDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Terumitsu SawaiDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Takeshi NagayasuDepartment of Surgical Oncology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimJapanese Gastric Cancer Treatment Guidelines do not recommend adjuvant chemotherapy after radical gastrectomy for pathological stage (p) T1N+ or pT2~3N0 gastric cancer. However, some patients experience disease recurrence. This study aimed to identify the risk factors for recurrence in pT1N+ or pT2-3N0 gastric cancer. PATIENTS AND

methodsThe study included 157 patients with diagnosed pT1N+ or pT2-3N0 gastric cancer who underwent radical gastrectomy at our institution between January 2001 and December 2020. Clinicopathological data and surgical data were obtained. Independent prognostic factors were analyzed using a Cox proportional hazards regression model.

resultsThirteen patients (8.3%) experienced disease recurrence. Multivariate analysis revealed that the number of examined lymph nodes was an independent prognostic factor for recurrence-free survival (hazard ratio=10.90; 95% confidence interval=1.39-85.86; p=0.023). The group with ≤35 examined lymph nodes had significantly worse recurrence-free survival compared with the group with ≥36 examined lymph nodes (80.7% versus 98.7%; p=0.0005).

conclusionThe number of examined lymph nodes (≤35) was an independent risk factor for recurrence after radical gastrectomy with pT1N+ or pT2-3N0 gastric cancer.

Indexed as

Examined lymph nodesgastric cancerpT1N+ or pT2-3N0recurrencerisk factor

Identifiers

PMID36060028
PMCPMC9425580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.